Episode
Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian
- Podcast
- Blood Cancer Talks
- Published
- Feb 12, 2025
- Duration seconds
- 3775
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/71e8c6ff
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-56-management-of-newly-diagnosed-cml-with-dr-hagop-kantarjian/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-56-management-of-newly-diagnosed-cml-with-dr-hagop-kantarjian.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/33414482/ 4. 10-year follow-up of CML-IV RCT (imatinib): https://pubmed.ncbi.nlm.nih.gov/25676422/ 5. MD Anderson data on low-dose dasatinib (50 mg): https://pubmed.ncbi.nlm.nih.gov/36054032/ https://pubmed.ncbi.nlm.nih.gov/31553487/ 6. CML: 2025 update on diagnosis, therapy, and monitoring: https://pubmed.ncbi.nlm.nih.gov/39093014/